Application of gene-editing technologies to HIV-1

被引:19
|
作者
Drake, Mary Jane [1 ]
Bates, Paul [1 ]
机构
[1] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
CRISPR/Cas9; gene editing; HIV-1; transcription activator-like effector nuclease; zinc finger nuclease; ANTIRETROVIRAL THERAPY; HUMAN-CELLS; CRISPR; GENERATION; LATENT; CAS9; ACTIVATION; INHIBITOR; MOUSE; CCR5;
D O I
10.1097/COH.0000000000000139
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review This review will highlight some of the recent advances in genome engineering with applications for both clinical and basic science investigations of HIV-1. Recent findings Over the last year, the field of HIV cure research has seen major breakthroughs with the success of the first phase I clinical trial involving gene editing of CCR5 in patient-derived CD4(+) T cells. This first human use of gene-editing technology was accomplished using zinc finger nucleases (ZFNs). Zinc finger nucleases and the advent of additional tools for genome engineering, including transcription activator-like effector nucleases (TALENS) and the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system, have made gene editing remarkably simple and affordable. Here we will discuss the different gene-editing technologies, the use of gene editing in HIV research over the past year, and potential applications of gene editing for both in-vitro and in-vivo studies. Summary Genome-engineering technologies have rapidly progressed over the past few years such that these systems can be easily applied in any laboratory for a variety of purposes. For HIV-1, upcoming clinical trials will determine if gene editing can provide the long-awaited functional cure. In addition, manipulation of host genomes, whether in vivo or in vitro, can facilitate development of better animal models and culture methods for studying HIV-1 transmission, pathogenesis, and virus-host interactions.
引用
收藏
页码:123 / 127
页数:5
相关论文
共 50 条
  • [1] Nucleases in gene-editing technologies: past and prologue
    Dan-Yuan Li
    Long-Qi Li
    Jun-Jie Gogo Liu
    [J]. National Science Open, 2023, 2 (05) : 25 - 56
  • [2] Responsible Use of Human Gene-Editing Technologies
    Dzau, Victor J.
    Cicerone, Ralph J.
    [J]. HUMAN GENE THERAPY, 2015, 26 (07) : 411 - 412
  • [3] Risk-appropriate regulations for gene-editing technologies
    Brookes, Graham
    Smyth, Stuart J.
    [J]. GM CROPS & FOOD-BIOTECHNOLOGY IN AGRICULTURE AND THE FOOD CHAIN, 2024, 15 (01): : 1 - 14
  • [4] Next generation of gene-editing technologies for respiratory research and medicine
    Ocana, S. Cuevas
    Valverde, A. L. Serna
    Reed, L.
    Hannan, N. R.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [5] Genomics and Gene-Editing Technologies Accelerating Grain Product Innovation
    Henry, Robert J.
    [J]. CEREAL FOODS WORLD, 2019, 64 (06)
  • [6] The Gene-Editing Conversation
    Nisbet, Matthew
    [J]. AMERICAN SCIENTIST, 2018, 106 (01) : 15 - 19
  • [7] Gene-editing nucleases
    Baker, Monya
    [J]. NATURE METHODS, 2012, 9 (01) : 23 - 26
  • [8] Gene-Editing Policy
    Nisbet
    [J]. AMERICAN SCIENTIST, 2018, 106 (03) : 132 - 132
  • [9] Gene-editing nucleases
    Monya Baker
    [J]. Nature Methods, 2012, 9 : 23 - 26
  • [10] Progress on Application of Conditional System in Gene-editing Pigs
    Liu Xiao-Yi
    Jin Qin
    Wang Ke-Pin
    Lai Liang-Xue
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2022, 49 (05) : 838 - 848